1. Meredith Y, Tarek A, Marilyn M, Bennett L, Rebecca N, Anne M, et al. Patient engagement at a tipping point—the need for cultural change across patient, sponsor, and regulator stakeholders: insights from the DIA conference. Thrapeutic Innov Regul Sci. 2016;50(5):546–53.
2. FDA, “Patient Preference Information – Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling;” 2016. Docket Number: FDA-2015-D-1580, 2016.
3. Center for Devices and Radiological Health (CDRH), “Guidance for Industry and Food and Drug Administration Staff: Factors to Conider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications,” Food and Drug Administration (FDA); 2016. Docket No. FDA-2011-D-0577, 2012.
4. Center for Devices and Radiological Health (CDRH), “Factors to consider when making benefit-risk determinations for medical device investigational device exemptions,” Food and Drug Administration (FDA); 2017. Docket No. FDA-2015-D-1777, 2017.
5. Center for Devices and Radiological Health (CDRH), “Factors to Consider Regarding BenefitRisk in Medical Device Product Availability, Compliance, and Enforcement Decisions,” Food and Drug Administration (FDA); 2016. Docket No. FDA-2016-D-1495, 2016.